Autologous Blood and Platelet-Rich Plasma Injection in Tendinopathy

Autologous blood and platelet-rich plasma (PRP) injection is a treatment in which a patient's own blood is processed and injected into an injured tendon with the aim of promoting healing and reducing pain. There is currently no harmonised Central East ICB clinical policy, find local area policies that have been transferred to Central East ICB where these exist.

Clinical policies aim to prevent avoidable harm to patients by only offering treatments on the NHS that are evidence-based, clinically safe and effective, as well as cost effective and a good use of resources.

Information:

Currently there is not a single clinical policy for autologous blood and platelet-rich plasma (PRP) injection in tendinopathy that applies to people across the whole Central East area.

Where a legacy Integrated Care Board (ICB) had an agreed clinical policy on autologous blood and platelet-rich plasma (PRP) injection in tendinopathy, this policy transferred to Central East ICB on 1 April 2026. Previously agreed policies will continue to apply only to people living in that former ICB’s area until any new policy is adopted by NHS Central East ICB.

Where an area doesn’t have a previously agreed policy on autologous blood and platelet-rich plasma (PRP) injection in tendinopathy, support for patients in that area will be based on a routine commissioning pathway.

Local clinical policy positions for autologous blood and platelet-rich plasma (PRP) injection in tendinopathy

Bedfordshire, Luton and Milton Keynes

Autologous blood and platelet-rich plasma (PRP) injection in tendinopathy

Cambridgeshire and Peterborough

Foot Care (Including platelet-rich plasma (PRP) injections)

Hertfordshire and West Essex

No policy (routine commissioning pathway via the Individual Funding Request (IFR) process)